Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Dropped to Sell by Wall Street Zen

Wall Street Zen lowered shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the company. Raymond James Financial reissued a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Canaccord Genuity Group started coverage on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, October 26th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $22.33.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ TNXP traded down $0.23 during trading hours on Friday, reaching $3.01. 1,924,597 shares of the stock were exchanged, compared to its average volume of 1,025,831. The firm has a market capitalization of $58.48 million, a price-to-earnings ratio of -0.25 and a beta of 1.90. Tonix Pharmaceuticals has a 52 week low of $2.90 and a 52 week high of $20.56. The stock’s fifty day simple moving average is $7.72 and its 200 day simple moving average is $11.85.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Monday, November 9th. The company reported ($2.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.39) by ($0.50). Tonix Pharmaceuticals had a negative net margin of 420.45% and a negative return on equity of 80.97%. The firm had revenue of $17.23 million during the quarter, compared to the consensus estimate of $16.32 million. Research analysts predict that Tonix Pharmaceuticals will post -10.42 EPS for the current fiscal year.

Insider Activity

In related news, CEO Seth Lederman purchased 2,000 shares of Tonix Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average price of $13.79 per share, with a total value of $27,580.00. Following the completion of the transaction, the chief executive officer directly owned 11,005 shares of the company’s stock, valued at $151,758.95. This represents a 22.21% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased 8,000 shares of company stock valued at $60,430 in the last three months. Insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in shares of Tonix Pharmaceuticals by 101.1% during the 1st quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock valued at $838,000 after acquiring an additional 30,644 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth $533,000. Great Lakes Advisors LLC bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth $303,000. Empowered Funds LLC acquired a new position in Tonix Pharmaceuticals in the third quarter valued at about $192,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Tonix Pharmaceuticals in the second quarter valued at about $92,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.